Ovarian Serous Adenocarcinoma — Trials

Ovarian Serous Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

151 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 69
Recruiting: 29
Ph III recruiting: 4
Growth YoY: —
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 42.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (20)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07791732	A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)	not yet recruiting	Phase 3	600	Daiichi SankyoINDUSTRY	0	Sep 1, 2026	clinicaltrials

Data updated 22 days agoSource updated Sep 1, 2026source: clinicaltrials